Genetic diversity and new therapeutic concepts

Area of Science:

• Pharmacogenomics
• Genetics
• Clinical Pharmacology

Background:

• Individual variability in drug response is a significant clinical problem, causing adverse reactions and treatment failures.
• Approximately 100,000 deaths and over 2 million hospitalizations in the US are linked to prescribed medications annually.
• Genetic factors in drug-metabolizing enzymes and target genes contribute to this interindividual variability.

Purpose of the Study:

• To highlight the importance of applying pharmacogenetic concepts in clinical practice.
• To discuss the potential of pharmacogenomics in the postgenomic era for personalized medicine.
• To address the challenges and limitations in translating pharmacogenetic knowledge into clinical practice.

Main Methods:

• Leveraging molecular tools from the human genome project, including SNP genotyping, HapMap, and microarrays.
• Identifying causal variations in target genes.
• Conducting genome-wide screening for multigene determinants of drug response.

Main Results:

• Pharmacogenetics offers a path beyond the "one size fits all" approach to drug therapy.
• Progress in the field is slower than expected due to complexities like multigene determinants.
• Successful translation requires high accuracy, precision, and regulatory oversight.

Conclusions:

• Pharmacogenomic data holds promise for enhancing medication safety and efficacy.
• Ethical, legal, and educational considerations are crucial for clinical implementation.
• Further development and education are necessary to realize the full potential of personalized pharmacotherapy.